Cathay Biotech Valuation
| 688065 Stock | 42.84 0.22 0.51% |
At this time, the firm appears to be overvalued. Cathay Biotech shows a prevailing Real Value of USD36.35 per share. The current price of the firm is USD42.84. Our model approximates the value of Cathay Biotech from analyzing the firm fundamentals such as Current Valuation of 21.78 B, profit margin of 0.14 %, and Return On Equity of 0.026 as well as examining its technical indicators and probability of bankruptcy.
Price Book 2.2061 | Enterprise Value 21.8 B | Enterprise Value Ebitda 45.825 | Price Sales 9.0427 | Trailing PE 63 |
Overvalued
Today
Please note that Cathay Biotech's price fluctuation is not too volatile at this time. Calculation of the real value of Cathay Biotech is based on 3 months time horizon. Increasing Cathay Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cathay Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cathay Stock. However, Cathay Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 42.84 | Real 36.35 | Hype 42.69 |
The real value of Cathay Stock, also known as its intrinsic value, is the underlying worth of Cathay Biotech Company, which is reflected in its stock price. It is based on Cathay Biotech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cathay Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cathay Biotech helps investors to forecast how Cathay stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cathay Biotech more accurately as focusing exclusively on Cathay Biotech's fundamentals will not take into account other important factors: Cathay Biotech Cash |
|
Cathay Biotech Total Value Analysis
Cathay Biotech is presently estimated to have takeover price of 21.78 B with market capitalization of 24.99 B, debt of 1.53 B, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Cathay Biotech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
21.78 B | 24.99 B | 1.53 B |
Cathay Biotech Investor Information
About 61.0% of the company shares are owned by insiders or employees . The book value of Cathay Biotech was presently reported as 19.74. The company last dividend was issued on the 24th of July 2024. Cathay Biotech had 1.4:1 split on the 20th of July 2022. Cathay Biotech is performing exceptionally good at this time. It has a great probability to report excellent financial results in January.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 625.2 M | 569.5 M |
|
| |||||
| Operating Income | 371.7 M | 273.3 M |
|
|
Cathay Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cathay Biotech has an asset utilization ratio of 11.23 percent. This suggests that the Company is making USD0.11 for each dollar of assets. An increasing asset utilization means that Cathay Biotech is more efficient with each dollar of assets it utilizes for everyday operations.Cathay Biotech Ownership Allocation
Cathay Biotech holds a total of 583.38 Million outstanding shares. Cathay Biotech shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 61.34 percent of Cathay Biotech outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cathay Biotech Profitability Analysis
The company reported the revenue of 2.11 B. Net Income was 366.52 M with profit before overhead, payroll, taxes, and interest of 2.44 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cathay Biotech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cathay Biotech and how it compares across the competition.
About Cathay Biotech Valuation
The stock valuation mechanism determines Cathay Biotech's current worth on a weekly basis. Our valuation model uses a comparative analysis of Cathay Biotech. We calculate exposure to Cathay Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cathay Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 608.8 M | 618.3 M |
Cathay Biotech Quarterly Retained Earnings |
|
Complementary Tools for Cathay Stock analysis
When running Cathay Biotech's price analysis, check to measure Cathay Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cathay Biotech is operating at the current time. Most of Cathay Biotech's value examination focuses on studying past and present price action to predict the probability of Cathay Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cathay Biotech's price. Additionally, you may evaluate how the addition of Cathay Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |